Molecular Partners (NASDAQ:MOLN) & Jade Biosciences (NASDAQ:JBIO) Head to Head Survey

Molecular Partners (NASDAQ:MOLN) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent ratings for Molecular Partners and Jade Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1	1	2	0	2.25
Jade Biosciences	1	1	6	2	2.90

Molecular Partners presently has a consensus price target of $8.38, indicating a potential upside of 115.85%. Jade Biosciences has a consensus price target of $47.13, indicating a potential upside of 114.20%. Given Molecular Partners’ higher possible upside, equities analysts clearly believe Molecular Partners is more favorable than Jade Biosciences.

Insider and Institutional Ownership

26.6% of Molecular Partners shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Molecular Partners and Jade Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65 million	27.73	-$74.41 million	($1.94)	-2.00
Jade Biosciences	N/A	N/A	-$127.41 million	($2.02)	-10.89

Molecular Partners has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Molecular Partners has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Jade Biosciences has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.

Profitability

This table compares Molecular Partners and Jade Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Jade Biosciences	N/A	-51.34%	-47.32%

Summary

Jade Biosciences beats Molecular Partners on 7 of the 13 factors compared between the two stocks.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

About Jade Biosciences

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.